Corvus Pharmaceuticals, Inc. (CRVS) financial statements (2020 and earlier)

Company profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:8611590135
Cash and cash equivalents939455
Other undisclosed cash, cash equivalents, and short-term investments777545130
Prepaid expense00  
Other current assets1011
Other undisclosed current assets1100
Total current assets:8811691136
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment2233
Other noncurrent assets1011
Total noncurrent assets:5344
TOTAL ASSETS:9211895140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4353
Accounts payable2232
Accrued liabilities0011
Employee-related liabilities2111
Debt1   
Deferred rent credit 0
Deferred revenue and credits00
Other undisclosed current liabilities4443
Total current liabilities:10796
Noncurrent Liabilities
Long-term debt and lease obligation3   
Operating lease, liability3
Liabilities, other than long-term debt 111
Other liabilities 111
Total noncurrent liabilities:3111
Total liabilities:128107
Stockholders' equity
Stockholders' equity attributable to parent8011085133
Common stock0000
Additional paid in capital286281208201
Accumulated other comprehensive income (loss)0(0)(0)(0)
Accumulated deficit(206)(170)(124)(68)
Total stockholders' equity:8011085133
TOTAL LIABILITIES AND EQUITY:9211895140

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Operating expenses(49)(49)(57)(37)
Operating loss:(49)(49)(57)(37)
Loss from continuing operations before equity method investments, income taxes:(49)(49)(57)(37)
Other undisclosed income from continuing operations before income taxes2211
Loss before gain (loss) on sale of properties:(46)(47)(56)(36)
Other undisclosed net loss(1)   
Net loss:(47)(47)(56)(36)
Other undisclosed net income attributable to parent1   
Net loss available to common stockholders, diluted:(46)(47)(56)(36)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss:(47)(47)(56)(36)
Comprehensive loss:(47)(47)(56)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(0)0
Comprehensive loss, net of tax, attributable to parent:(46)(47)(56)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: